Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

AXGN

AXGN News

Newswire

17:13

Axogen shares surge 15.90% after-hours following FDA approval of Avance nerve repair biologic and analyst price target upgrades.

14:46

Axogen: Jefferies Maintains Buy Rating, Raises PT to $36 from $29

13:16

Axogen: Lake Street maintains Buy, PT raised to $40 from $30.

11:50

Axogen shares surge 20.01% intraday on FDA approval of Avance biologics license application, transitioning product to FDA-approved biologic.

09:57

Axogen shares rise 10.62% intraday after FDA approves AVANCE® acellular nerve allograft for peripheral nerve injury treatment in adults and children.

View More

About AXGN

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More